TrialCancer immunology, immunotherapy : CII2026

Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis.

Hung-Yang Kuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.